Numerous studies reported that MET deregulation by overexpression, activating mutations, splicing variants and amplification is implicated in tumour development and progression [55], positioning MET as therapeutic target for the treatment of cancer, including HCC [56]. The gene discussed is MET; the disease is hepatocellular carcinoma.